-
Ciltacabtagene autoleucel, sold
under the
brand name
Carvykti, is an anti-cancer
medication used to
treat multiple myeloma.
Ciltacabtagene autoleucel is...
-
Risperdal Consta Spravato Topamax Trevicta Xeplion Oncology therapies Balversa Carvykti Dacogen Darzalex Eprex Erleada Imbruvica Procrit Rybrevant Talvey Tecvayli...
-
Biologics Evaluation and
Research (2022-03-21). "
CARVYKTI". FDA.
European Medicines Agency (2023-07-27). "
Carvykti". EMA. Research,
Center for Drug Evaluation...
- have
received at
least four
prior therapies Ciltacabtagene autoleucel (
Carvykti) was
approved for
medical use in the
United States in
February 2022. Ciltacabtagene...
-
Cartrol carubicin (INN)
carumonam (INN)
carvedilol (INN)
carvotroline (INN)
Carvykti carzelesin (INN)
carzenide (INN)
Casgevy casimersen casirivimab and imdevimab...
-
endothelial growth factor peripheral artery disease Ciltacabtagene autoleucel (
Carvykti):
treatment for
multiple myeloma Delandistrogene moxeparvovec (Elevidys):...
-
Tecartus (brexucabtagene autoleucel),
Breyanzi (lisocabtagene maraleucel),
Carvykti (ciltacabtagene autoleucel),
Abecma (idecabtagene vicleucel), and Kymriah...
-
Legend Biotech was
listed on the
NASDAQ under the
symbol "LEGN". In 2022,
Carvykti, a CAR-T cell
therapy developed by
Janssen Biotech and
Legend Biotech,...
-
served on the ODAC
committee and
helped with the
approval of
CiltaCel (
Carvykti) in the
second line of
therapy of
Multiple Myeloma. In
April 2024, she...
- vicleucel)". FDA. Research,
Center for
Biologics Evaluation and (2023-02-24). "
CARVYKTI". FDA. Ruella, Marco; Xu, Jun; Barrett,
David M.; Fraietta,
Joseph A.;...
